CARsgen Therapeutics Holdings Limited
CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma (R/R MM). The company is also developing… Read more
CARsgen Therapeutics Holdings Limited - Asset Resilience Ratio
CARsgen Therapeutics Holdings Limited (CRTHF) has an Asset Resilience Ratio of 18.53% as of April 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2021)
This chart shows how CARsgen Therapeutics Holdings Limited's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down CARsgen Therapeutics Holdings Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $490.09 Million | 18.53% |
| Total Liquid Assets | $490.09 Million | 18.53% |
Asset Resilience Insights
- Good Liquidity Position: CARsgen Therapeutics Holdings Limited maintains a healthy 18.53% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
CARsgen Therapeutics Holdings Limited Industry Peers by Asset Resilience Ratio
Compare CARsgen Therapeutics Holdings Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for CARsgen Therapeutics Holdings Limited (2015–2021)
The table below shows the annual Asset Resilience Ratio data for CARsgen Therapeutics Holdings Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-10-31 | 66.06% | $2.32 Billion | $3.51 Billion | -- |
| 2018-10-31 | 0.00% | $0.00 | $1.58 Billion | -- |
| 2017-10-31 | 0.00% | $0.00 | $1.48 Billion | -- |
| 2016-10-31 | 0.00% | $0.00 | $1.41 Billion | -- |
| 2015-10-31 | 0.00% | $0.00 | $1.25 Billion | -- |